MedTrace Logo

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

NCT04331899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-11-30

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.

Conditions

Interventions

DRUG

Peginterferon Lambda-1a

Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care

OTHER

Placebo

Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection

Sponsors & Collaborators

Principal Investigators

  • Upinder Singh · Professor (Medicine-Infectious Diseases)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-25
Primary Completion
2020-08-14
Completion
2021-05-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04331899 on ClinicalTrials.gov